X

Vous n'êtes pas connecté

Rubriques :

  - DRUGS.COM - Pharma Industry News - 23/Jun 19:54

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.Monjuvi is a humanized Fc-modified cytolytic CD19-targeting...

Articles similaires

Sorry! Image not available at this time

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

drugs.com - 23/Jun 19:54

MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with...

Sorry! Image not available at this time

Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

drugs.com - 18/Jun 04:06

WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 18, 2025-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Sorry! Image not available at this time

Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

drugs.com - 20/Jun 00:06

TARRYTOWN, N.Y. and PARIS, June 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S....

Sorry! Image not available at this time

FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema

drugs.com - 16/Jun 06:06

KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL today announced the U.S. Food and Drug Administration (FDA)...

Sorry! Image not available at this time

FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema

drugs.com - 16/Jun 06:06

KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL today announced the U.S. Food and Drug Administration (FDA)...

Sorry! Image not available at this time

FDA Approves Once-Monthly Andembry for Hereditary Angioedema

drugs.com - 20/Jun 21:31

FRIDAY, June 20, 2025 -- The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa...

Sorry! Image not available at this time

FDA Approves Once-Monthly Andembry for Hereditary Angioedema

drugs.com - 20/Jun 21:31

FRIDAY, June 20, 2025 -- The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa...

Sorry! Image not available at this time

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

drugs.com - 11/Jun 23:06

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a...

Sorry! Image not available at this time

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

drugs.com - 11/Jun 23:06

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a...

Sorry! Image not available at this time

FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy

drugs.com - 13/Jun 22:06

RAHWAY, N.J.--(BUSINESS WIRE) June 13, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S....

Les derniers communiqués